Abstract
The mechanism for the chemoresistance of cancer cells is quite complicated. Most of the anti-cancer drugs are known to induce apoptosis in cancer cells, as well as in normal cells, in part by the activation of the p53 pathway. p53 is often referred to as the 'guardian of the genome' and is one of the most investigated tumor suppressor genes. A majority of human tumors harbor p53 mutations which can influence the effect of chemotherapy. Thus pre-therapeutic evaluation of the p53 gene can be extremely informative for patients with diverse malignancies. In this mini review, we introduce a p53 functional analysis system in mammalian cells, which can identify different types of p53 abnormalities, such as loss of function, dominant negative function, or gain of oncogenic function. The kinetic analysis of mutated-p53 may help to determine the therapeutic strategy in the individual patients with several malignancies. Furthermore, detailed information on the mutated p53 gene in cancer cells might provide useful suggestions for developing new anti-cancer drugs.
Keywords: Chemoresistance, head and neck cancer, oncogenic mutation, p53, p53-target genes, tumor suppressor gene.
Graphical Abstract
Current Signal Transduction Therapy
Title:Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
Volume: 11 Issue: 1
Author(s): Daisuke Uchida, Hitoshi Kawamata, Fujiyuki Inaba, Ichio Fukasawa and Takahiro Fujimori
Affiliation:
Keywords: Chemoresistance, head and neck cancer, oncogenic mutation, p53, p53-target genes, tumor suppressor gene.
Abstract: The mechanism for the chemoresistance of cancer cells is quite complicated. Most of the anti-cancer drugs are known to induce apoptosis in cancer cells, as well as in normal cells, in part by the activation of the p53 pathway. p53 is often referred to as the 'guardian of the genome' and is one of the most investigated tumor suppressor genes. A majority of human tumors harbor p53 mutations which can influence the effect of chemotherapy. Thus pre-therapeutic evaluation of the p53 gene can be extremely informative for patients with diverse malignancies. In this mini review, we introduce a p53 functional analysis system in mammalian cells, which can identify different types of p53 abnormalities, such as loss of function, dominant negative function, or gain of oncogenic function. The kinetic analysis of mutated-p53 may help to determine the therapeutic strategy in the individual patients with several malignancies. Furthermore, detailed information on the mutated p53 gene in cancer cells might provide useful suggestions for developing new anti-cancer drugs.
Export Options
About this article
Cite this article as:
Uchida Daisuke, Kawamata Hitoshi, Inaba Fujiyuki, Fukasawa Ichio and Fujimori Takahiro, Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene, Current Signal Transduction Therapy 2016; 11 (1) . https://dx.doi.org/10.2174/1574362411999160606163438
DOI https://dx.doi.org/10.2174/1574362411999160606163438 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibition of Cellular Proliferation by Drug Targeting of Cyclin-Dependent Kinases
Current Pharmaceutical Biotechnology Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Analysis of Simple Sequence Repeats in Mammalian Cell Cycle Genes
Recent Advances in DNA & Gene Sequences (Discontinued) Irreversible Multitargeted ErbB Family Inhibitors for Therapy of Lung and Breast Cancer
Current Cancer Drug Targets Notch Signaling: A Potential Therapeutic Target in Prostate Cancer
Current Cancer Drug Targets New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide
Current Cancer Drug Targets Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Engineered Nanoparticles in Cancer Therapy
Recent Patents on Drug Delivery & Formulation Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer
Current Medicinal Chemistry Ent-11α-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells
Current Drug Targets Platinum-Based Agents for Individualized Cancer Treatment
Current Molecular Medicine Stem Cell Based Preclinical Drug Development and Toxicity Prediction
Current Pharmaceutical Design Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Personalization of Targeted Therapy in Advanced Thyroid Cancer
Current Genomics Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical Candidates
Anti-Cancer Agents in Medicinal Chemistry The Emerging Role of EMT-related lncRNAs in Therapy Resistance and their Applications as Biomarkers
Current Medicinal Chemistry A Functional Scaffold in Marine Alkaloid: An Anticancer Moiety for Human
Current Medicinal Chemistry Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Marine Derived Anticancer Drugs Targeting Microtubule
Recent Patents on Anti-Cancer Drug Discovery